Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co. Inc. daily Stock Chart
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E34.18 EPS (ttm)1.64 Insider Own0.04% Shs Outstand2.85B Perf Week-0.02%
Market Cap159.13B Forward P/E14.87 EPS next Y3.76 Insider Trans-10.94% Shs Float2.77B Perf Month-0.41%
Income4.62B PEG10.20 EPS next Q0.91 Inst Own74.70% Short Float1.07% Perf Quarter6.64%
Sales39.39B P/S4.04 EPS this Y-61.60% Inst Trans-0.35% Short Ratio3.48 Perf Half Y7.27%
Book/sh15.79 P/B3.54 EPS next Y1.10% ROA4.60% Target Price61.60 Perf Year-0.15%
Cash/sh4.54 P/C12.29 EPS next 5Y3.35% ROE10.20% 52W Range44.16 - 58.06 Perf YTD7.59%
Dividend1.84 P/FCF27.34 EPS past 5Y41.50% ROI6.40% 52W High-3.76% Beta0.66
Dividend %3.29% Quick Ratio1.30 Sales past 5Y-3.00% Gross Margin62.80% 52W Low26.53% ATR0.89
Employees68000 Current Ratio1.60 Sales Q/Q-1.20% Oper. Margin18.20% RSI (14)47.59 Volatility1.41% 1.35%
OptionableYes Debt/Eq0.59 EPS Q/Q20.60% Profit Margin11.70% Rel Volume2.02 Prev Close57.68
ShortableYes LT Debt/Eq0.54 EarningsJul 29 BMO Payout110.40% Avg Volume8.50M Price55.88
Recom2.50 SMA20-0.97% SMA500.70% SMA2006.91% Volume17,215,990 Change-3.12%
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Jun-24-16 04:39PM  Brexit may make health care stocks a good defensive play at MarketWatch
09:42AM  Why Investors Are Paying a Premium for These 3 Drugmakers at Motley Fool
08:00AM  Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29 Business Wire
03:22AM  German pharma lobby says EU drug regulator must leave London Reuters
Jun-23-16 05:01PM  Sanofi's Likely Sweetener for Medivation Panned
10:59AM  Incyte Reports Epacadostat Combination Study Initiation
Jun-22-16 02:05PM  Whats so groundbreaking about Curis new cancer drug that just began human trials? at bizjournals.com
01:50PM  U.S. stocks come under stress as Brexit vote looms at MarketWatch
12:20PM  The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All at Insider Monkey
Jun-20-16 12:30PM  Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe Business Wire
09:30AM  The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
04:46AM  Calls For Actions Grow Louder
Jun-19-16 03:03PM  Gilead Sciences: Where's the Value? at Motley Fool
07:23AM  3 Top Big Pharma Stocks to Buy Now at Motley Fool
Jun-18-16 11:00AM  Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital
Jun-17-16 04:44PM  U.S. stocks fall as Brexit jitters cast long shadow at MarketWatch
04:16PM  Stocks Fall Ahead Of Brexit Vote; Bad News For Apple
11:06AM  Dow 30 Stock Roundup: Microsoft Acquires LinkedIn, Merck to Buy Afferent Pharmaceuticals
09:45AM  Will Merck Keytruda Surpass Bristol-Myers Opdivo In Immunotherapies Race?
07:35AM  Merck: Keytruda works better than chemotherapy for lung cancer patients at bizjournals.com
Jun-16-16 08:33PM  Jim Cramer's 'Mad Money' Recap: An Epic Battle of 'Brexit' vs. Oil
07:00PM  Merck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer Battle at Motley Fool
05:12PM  This Key Merck Cancer Drug Just Got a Huge Boost at Fortune
04:52PM  Stocks snap 5-day losing streak; Dow reverses triple-digit loss at MarketWatch
04:46PM  Cavium and Marathon Oil skid, while Kroger and Newmont rise
04:39PM  Mercks Keytruda Extends Lung Cancer Survival As Sole Therapy
04:30PM  U.S. Stocks End Slump As Dow Leads; Merck Gains, But Nike Falls
04:01PM  Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
03:29PM  Stocks Recover To Trade Higher; Acacia Communications Breaks Out
02:58PM  Stocks Cut Losses; Merck Hoists Dow; Hedge Funds Dumping Apple
02:19PM  Now Is the Time to Buy Merck, Cramer Says
11:04AM  Jim Cramer -- Merck Should Be Higher on Positive Treatment News
10:04AM  Nasdaq Undercuts 200-Day; Kroger, Merck Stocks Climb
09:54AM  Cramer's Stop Trading: 'Breakthrough' for Merck
09:36AM  Merck's Keytruda prolongs life in big lung-cancer study
08:15AM  Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer
08:00AM  Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress Business Wire
07:38AM  Merck's stock surges on positive results from cancer-treatment study at MarketWatch
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Business Wire
Jun-15-16 10:23PM  A legendary CEO did something unimaginable by todays standards, and it tells you everything about how America has changed
04:46PM  Relypsa Sales Numbers Surprise to the Upside
03:24PM  This Fund Wants to Make It Easier to Invest in Biotech Stocks at Fortune
08:30AM  Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016 Business Wire
Jun-14-16 06:14PM  Merck's Biosimilar Version of Lantus Tops Phase III Studies
04:44PM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
11:08AM  Merck & Co. (MRK) Stock Sliding, Jefferies Lowers Price Target
08:08AM  Should Pfizer Buy This Beaten-Down Immuno-Oncology Company? at Motley Fool
Jun-13-16 05:17PM  This Diabetes Drug Saves Lives. You Can Thank The FDA at Forbes
04:08PM  5 Things Organovo Holdings, Inc. Management Wants You to Know at Motley Fool
01:15PM  Merck receives a big vote of confidence
01:03PM  Tricking the Common Cold Into Destroying Cancer at Motley Fool
12:34PM  Merck Stock Trades Ex-Dividend Monday (MRK) at Investopedia
11:00AM  New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children PR Newswire
10:30AM  Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus® Business Wire
08:50AM  Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
03:57AM  Merck & Co., Inc. :MRK-FR: Earnings Analysis: Q1, 2016 By the Numbers : June 13, 2016
03:16AM  ECB Bond Buying Destabilizes All Financial Markets
Jun-12-16 02:00PM  Put Agenus, Progenics on Your Small-Cap List
Jun-11-16 11:00AM  Merck, Pfizer Double Size of Diabetes Drug Study to Catch Rivals at Bloomberg
11:00AM  Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes Business Wire
Jun-10-16 11:50AM  $1.25B deal: Merck to buy California biopharm firm with potential chronic cough treatment at bizjournals.com
11:11AM  Merck Testing 13-Year Resistance (MRK) at Investopedia
10:39AM  Merck acquires Pappas-backed biotech company in deal that could reach $1.25 billion at bizjournals.com
10:05AM  Q&A: After scoring 2nd big deal in 5 years, is this CEO the Steph Curry of biotech? at bizjournals.com
08:53AM  Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
08:17AM  Pre-Market Primer: Why Investors Will be Watching Tesla, Merck, and Three Other Stocks Today at Insider Monkey
08:05AM  Major Pharma Has Short Sellers on the Run at 24/7 Wall St.
07:00AM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
Jun-09-16 09:58PM  Big Pharma bombshell: Judge finds Merck lied in patent trial, overturns $200-million verdict at Los Angeles Times
08:53PM  Biotech vet hits jackpot again with $1.2 billion buyout of Peninsula company at bizjournals.com
08:47PM  Merck to purchase biotech Afferent for at least $500 million at MarketWatch
06:37PM  [$$] Merck to Acquire Biotech Company Afferent at The Wall Street Journal
06:37PM  Merck to Bulk Up With Afferent
06:34PM  Merck to buy biotech drug developer Afferent Pharmaceuticals
05:57PM  U.S. panel backs approval for Merck infectious diarrhea drug Reuters
05:07PM  Merck to Acquire Afferent Pharmaceuticals Business Wire
03:57PM  U.S. regulatory panel backs approval for Merck C. difficile drug Reuters
05:02AM  Consumer Health To Play A Pivotal Role In Merck's Africa Growth Strategy CNW Group
Jun-08-16 04:01PM  Dont Get Caught With These 5 Stocks Ahead of Earnings Season
02:37PM  Will Gilead (GILD) Stock Be Helped by Hepatitis C Drug Patents Case Win?
02:22PM  Here's Why You Should Buy Merck on Weakness
01:32PM  Gilead Sciences: After Hepatitis C Court Victory, an Earnings Boost at Barrons.com
12:06PM  What Are the Changes in AstraZenecas Profitability?
05:30AM  What To Look For In a Successful Money Manager Today: Character and Integrity
01:53AM  Judge Sides With Gilead Against Merck in Case Over Hepatitis C Drug Patents at The Wall Street Journal
Jun-07-16 09:00PM  Legal Dispute Puts Ionis Pharmaceuticals' Payday on Hold at Motley Fool
04:41PM  Judge throws out Mercks $200 million verdict over Gilead at MarketWatch
03:45PM  Why Gilead May Not Have to Pay Merck $200 Million After All at Fortune
03:30PM  Gilead Sciences: 'Egregious Misconduct' as Merck Hepatitis C Decision Reversed at Barrons.com
09:55AM  FDA staff question efficacy of Merck's drug for infectious diarrhea Reuters
08:54AM  FDA staff review questions efficacy of Merck's C. difficile drug Reuters
08:14AM  Put sale sees limit to downside in Merck
Jun-06-16 09:56PM  Gilead escapes liability in hepatitis C patent fight with Merck Reuters
08:32PM  Gileads escapes liability in hepatitis C patent fight with Merck Reuters
05:04PM  Bristol-Myers Hits 17-Year High Showing Off Cancer Portfolio
04:46PM  Merck (MRK) Reveals Data from Ongoing Studies on Keytruda
01:40PM  How Credit Suisse Views Major Pharma After ASCO at 24/7 Wall St.
01:20PM  Relypsa: Largest Institutional Shareholders are Buying More Stock
10:52AM  Pfizer (PFE) Presents Data on Utomilumab for Solid Tumors
09:41AM  The 8 'Dogs Of The Dow' For 2016 Continue To Outperform The Average at Forbes
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM